4D Molecular Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

4D Molecular Therapeutics

09/08/2023 22:30

* 4D Molecular Therapeutics Inc  FDMT.OQ  reported a
quarterly
adjusted loss of 77 cents​​ per share for the quarter ended in
June. The mean expectation of six analysts for the quarter was
for a loss of 81 cents per share.
    * Revenue rose 47.5% to $239.00 thousand from a year ago;
analysts
expected $848.33 thousand. 
    * 4D Molecular Therapeutics Inc's reported EPS for the
quarter was
a loss of 77 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.4%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * 4D Molecular Therapeutics Inc shares had fallen by 6.4%
this
quarter and lost 23.8% so far this year.
    * The company reported a quarterly loss of $29.62 million.
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $34.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 9 at 09:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.81          -0.77          Beat
 Mar. 31 2023      -0.89          -0.88          Beat
 Dec. 31 2022      -0.79          -0.84          Missed
 Sep. 30 2022      -0.91          -0.79          Beat